Details for: GLEEVEC
Company: NOVARTIS PHARMACEUTICALS CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02253275 | GLEEVEC | IMATINIB (IMATINIB MESYLATE) | 100 MG | TABLET | ORAL |
| 02253283 | GLEEVEC | IMATINIB (IMATINIB MESYLATE) | 400 MG | TABLET | ORAL |
Summary Reports
Summary Safety Review - Imatinib Mesylate (GLEEVEC and generics) - Assessing the Risk of Decline in Kidney Function During Long-Term Treatment
Summary Safety Review - Bcr-Abl Tyrosine Kinase Inhibitors - Assessing the Potential Harm to the Fetus
Summary Safety Review - Imatinib mesylate (GLEEVEC and generics) - Assessing the potential risk of tendon disorders
Summary Safety Review - Bcr-Abl Tyrosine Kinase Inhibitors - Assessing the Potential Harm to the Fetus
Summary Safety Review - Imatinib mesylate (GLEEVEC and generics) - Assessing the potential risk of tendon disorders
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.